KKR & Co agreed to invest €50m ($54m) in Univercells, an innovative bioprocessing provider focused on increasing the availability of affordable biologics. "KKR, through Gamma Biosciences, seeks to back innovative and impactful next-generation bioprocessing technologies, which is why we are excited to be investing in Univercells and its mission to deliver affordable biologics and gene therapies globally. Furthermore, we are excited to be working with Hugues and his team, who have a fantastic track record of building innovative biomanufacturing companies," Kugan Sathiyanandarajah, KKR Director and Head of Europe for Health Care Strategic Growth.